TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07082725: A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

Sponsor: Azafaros B.V. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 72 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT07082725 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07082725 Rescue Dossier →